Dr. Patrick Ess of American Chiropractic (Stanley Wellness) Shares Insights on Six Zones of Healing in Zone Therapy in HelloNation
By GlobeNewswire Published on June 27, 2025, 01:44 IST
LOCUST, N.C, June 26, 2025 (GLOBE NEWSWIRE) — What makes Zone Therapy an effective option for patients whose symptoms persist despite conventional treatment? That question is explored by Dr. Patrick Ess of American Chiropractic (Stanley Wellness) in a HelloNation article that outlines how this technique targets underlying regulatory imbalances through six defined body zones. According to Dr. Ess, many patients fail to find lasting relief not due to misdiagnosis but because core physiological systems remain unbalanced—something Zone Therapy aims to address directly.
Zone Therapy organizes the body into six primary systems: glandular, eliminative, nervous, digestive, muscular, and circulatory. These zones are governed by neurological pathways that can be accessed by stimulating specific points on the skull. Dr. Ess emphasizes that this technique doesn't add substances or suppress symptoms but helps restore internal balance through the body's own response mechanisms. Outcomes commonly reported by patients include improved energy, digestion, and sleep—indicators that internal signals between regulatory systems are becoming more coherent and functional.
The article highlights that Zone Therapy may be particularly helpful for those dealing with fatigue, hormonal fluctuations, or digestive complaints that don't resolve through standard interventions. Its holistic, non-invasive approach allows the body to engage in self-repair by strengthening communication within its internal networks. This approach is especially valuable for chronic symptom management and long-term wellness.
To read the full article, visit Understanding the Six Zones of Healing in Zone Therapy .
About HelloNation
HelloNation is a premier media platform that connects readers with trusted professionals and businesses across various industries. Through its innovative 'edvertising' approach that blends educational content and storytelling, HelloNation delivers expert-driven articles that inform, inspire, and empower. Covering topics from home improvement and health to business strategy and lifestyle, HelloNation highlights leaders making a meaningful impact in their communities.
Patrick McCabe
[email protected]
www.hellonation.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9070ffae-bbe7-4470-9881-b6d43cb475e3
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025 Marks the first submitted Clinical Trial Application (CTA) advancing ProQR's Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) — ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases. 'The submission of this CTA marks a significant milestone for ProQR, representing the first to advance our Axiomer RNA editing platform and pipeline into clinical development,' said Cristina Lopez Lopez, MD, PhD Chief Medical Officer of ProQR. 'This step brings us into the clinic with AX-0810 as we initiate a Phase 1 study to evaluate safety and target engagement in healthy volunteers. Cholestatic liver diseases represent an area of high unmet medical need and by targeting NTCP, AX-0810 introduces a novel therapeutic approach underpinned by human genetics and compelling preclinical data.' The proposed Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AX-0810 in healthy adult volunteers. The study will also explore biomarkers to assess early signals of target engagement. Pending regulatory clearance, the study is expected to commence at a single site in the Netherlands with initial data anticipated in Q4 2025. About AX-0810 AX-0810 is an investigational GalNac-delivered RNA editing oligonucleotide designed to treat cholestatic liver disease by targeting NTCP. These diseases are driven by toxic bile acid accumulation due to impaired bile flow, leading to progressive liver damage. AX-0810 offers a novel therapeutic approach by selectively modulating NTCP function, which decreases bile acid reuptake into the liver. This mechanism is supported by human genetics data showing that naturally occurring NTCP variants safety reduce bile acid reuptake, reinforcing the potential of NTCP modulation by ADAR-mediated RNA editing to improve liver health and alter the course of cholestatic disease. About Axiomer™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer 'Editing Oligonucleotides', or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease. About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell's own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Learn more about ProQR at Forward Looking Statements for ProQR This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'continue,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'look forward to', 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our business, ; our Axiomer™ RNA editing technology platform, including the continued development and advancement of our Axiomer platform, the advancement of AX-0810 to clinical trials, including the timing of, and our ability to obtain regulatory clearance; our expectations regarding the initiation of the planned Phase 1 clinical study of AX-0810 in the Netherlands, including our ability to recruit for and complete the study, and the anticipated timing of initial data in Q4 2025; the plan, timing, progress and results of our preclinical studies, planned clinical trials and other development activities, including the release of data related thereto, and the potential of our technologies and product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers or suppliers to supply materials for research and development and the risk of supply interruption or delays from suppliers or contract manufacturers; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. ProQR Therapeutics N.V. Investor and media contact:Sarah KielyProQR Therapeutics N.V.T: +1 617 599 6228 [email protected] or Investor contact: Peter KelleherLifeSci AdvisorsT: +1 617 430 7579 [email protected]
Business Upturn
5 hours ago
- Business Upturn
Basel Medical Obtains Waiver of Lock-Up for Potential Strategic Fund Raising
Singapore, June 26, 2025 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL) (the 'Company'), today announced that Cathay Securities, Inc., as the representative of the several underwriters of the Company's initial public offering, has granted its consent on June 23, 2025 to the lock-up provision in the underwriting agreement dated February 24, 2025, permitting (i) a public offering or private placement of new securities of the Company, and (ii) the filing with the U.S. Securities and Exchange Commission of a registration statement under the Securities Act of 1933 in relation to such offering or placement, prior to the expiration of the lock-up period which was due to expire six months from the closing of the initial public offering. The Company is evaluating its capital requirements and reviewing its options with regards to fund-raising through the issuance of securities. As at the date hereof, there is no certainty that any such fund-raising or securities issuance will be consummated. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, and neither shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Basel Medical Group Ltd Basel Medical is a Singapore-based provider of orthopedic and trauma services, general practice, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments. Our operations are based in Singapore, with our clinics being at 6 Napier Road, Unit #02-10/11 and Unit #03-07, Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of corporations, in particular those in the construction, marine and oil & gas industries, which underpin our robust business model. As an orthopedic service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, government effort and expenditure on healthcare, growing sports participation rate and Singapore's position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, corporate finance and healthcare partnership specialists. The Company completed the acquisition of Bethesda Medical, a leading Singapore-based healthcare provider specializing in diagnostic imaging, sports medicine, health screening services, general outpatient care, mental and women's health services, in April 2025. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company's website: Forward-Looking Statements Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as 'aim', 'anticipate', 'believe', 'estimate', 'expect', 'going forward', 'intend', 'may', 'plan', 'potential', 'predict', 'propose', 'seek', 'should', 'will', 'would' or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC. Media Contact: Basel Medical Group LtdPhone: +65 6291 9188 Email: [email protected] Website:
Business Upturn
5 hours ago
- Business Upturn
Dr. Patrick Ess of American Chiropractic (Stanley Wellness) Shares Insights on Six Zones of Healing in Zone Therapy in HelloNation
By GlobeNewswire Published on June 27, 2025, 01:44 IST LOCUST, N.C, June 26, 2025 (GLOBE NEWSWIRE) — What makes Zone Therapy an effective option for patients whose symptoms persist despite conventional treatment? That question is explored by Dr. Patrick Ess of American Chiropractic (Stanley Wellness) in a HelloNation article that outlines how this technique targets underlying regulatory imbalances through six defined body zones. According to Dr. Ess, many patients fail to find lasting relief not due to misdiagnosis but because core physiological systems remain unbalanced—something Zone Therapy aims to address directly. Zone Therapy organizes the body into six primary systems: glandular, eliminative, nervous, digestive, muscular, and circulatory. These zones are governed by neurological pathways that can be accessed by stimulating specific points on the skull. Dr. Ess emphasizes that this technique doesn't add substances or suppress symptoms but helps restore internal balance through the body's own response mechanisms. Outcomes commonly reported by patients include improved energy, digestion, and sleep—indicators that internal signals between regulatory systems are becoming more coherent and functional. The article highlights that Zone Therapy may be particularly helpful for those dealing with fatigue, hormonal fluctuations, or digestive complaints that don't resolve through standard interventions. Its holistic, non-invasive approach allows the body to engage in self-repair by strengthening communication within its internal networks. This approach is especially valuable for chronic symptom management and long-term wellness. To read the full article, visit Understanding the Six Zones of Healing in Zone Therapy . About HelloNation HelloNation is a premier media platform that connects readers with trusted professionals and businesses across various industries. Through its innovative 'edvertising' approach that blends educational content and storytelling, HelloNation delivers expert-driven articles that inform, inspire, and empower. Covering topics from home improvement and health to business strategy and lifestyle, HelloNation highlights leaders making a meaningful impact in their communities. Patrick McCabe [email protected] A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
